
-
Protagonist Therapeutics NasdaqGM:PTGX Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Location: 7707 Gateway Boulevard, Newark, CA, 94560, United States | Website: https://www.protagonist-inc.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.386B
Cash
574.4M
Avg Qtr Burn
N/A
Short % of Float
11.45%
Insider Ownership
1.14%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Icotrokinra (JNJ-2113) (PN-235) Details Psoriasis | Phase 3 Data readout | |
Rusfertide (PTG-300) Details Blood cancer, Polycythemia vera, Cancer | Phase 3 Update | |
Icotrokinra (JNJ-2113, formerly PN-235) Details Ulcerative colitis | Phase 2b Update | |
PN-943 (α4β7-Integrin Antagonist) Details Inflammatory bowel disease, Inflammatory disease | Failed Discontinued | |
PTG-200 (IL-23R Antagonist) Details Crohns disease, Inflammatory bowel disease, Inflammatory disease | Failed Discontinued | |
Rusfertide (PTG-300) (Hepcidin Mimetic) Details Genetic disorder, Rare genetic disease | Failed Discontinued |